Helsinki, September 9, 2021 (PRNewswire) – Nanofom Finland Plc. The results of the Neurophysical Factor, Nanoform Certification Theory (PPC) project announced today that the nanoformification process has been successfully implemented for the herringis rhCDNF drug candidate.
As stated earlier in the press release February 9, 2021, The purpose of the project is to assess the potential of nanoform platform technology. The project includes a combination of hernias’ parakinesis disease with nanoparticle nanoparticular technology (CDNF therapy) combined with nanophobic nanopoietic article technology.
The PoC project shows that the nanoforming process can be successfully implemented for rhCDNF. Most importantly, in the process of nanoparticle formation, the rhCDNF protein maintains its structure, function, effectiveness, and neurotransmitters in accordance with CDNF regulators. After ensuring that the nanoform rhCDNF nanoparticles maintain stability and mobility, the project will move to the next stage – process verification study to further refine the size and shape of the nanoform rhCDNF nanoparticles and evaluate multi-distribution following in-line delivery.
“We are pleased with these initial results that show that nanofoaming is effective in the Herringis’ rhCDNF program. Christian Jones, CEO of Nanofom.
“This is one of the key milestones in the development of Parkinson’s disease as part of a broader local governance project for the rhCDNF. The ability to nanoform the rhCDNF molecule improves the chances of success in internal management. And creates additional opportunities to influence patients’ lives. We look forward to working with Nanofom. ” Craig Cook, CEO of Herringis Pharmacy.
Please contact us for more information
Christian Jones, Chief Commercial Officer
firstname.lastname@example.org / +44 7804 474 771
For investor relationship questions, please contact
Henry von Hartman, Director of Investment Relations
email@example.com / +46 7686 650 11
Nanofom is a company that invents innovative nanoparticles. Nanofum works with pharmaceutical and biotech partners around the world to provide hope to patients by developing new and improved drugs using nanoform platform technologies. The company focuses on reducing clinical damage and improving the performance of drug molecules through its nanotechnology and location services. Nanofom capabilities include GMP production, and its services range from small to large molecular development, focusing on solving and solving key issues in bioavailability and enabling new pharmaceutical applications. Nanofom shares listed in Nasdaq First North Growth Market Premier Helsinki (Marker: NANOFH) and Stockholm (Marking – NANOFS). Certified Consultant Dansk Bank A.S. Finland Branch, +358 40 744 1900. For more information, please visit http://www.nanoform.com
Nanophos – Future Statements
This press release contains a series of future statements, including a statement on the monopoly strategy, business plans and focus. The words can be “”, “”, “can,” “do,” “expect,” “expect,” “plan,” “guess,” “think,” believe, “guess,” “predict,” “project.” . , “Potential,” “Continue,” “Target,” and similar expressions are intended to identify future vision statements, although not all forward-looking statements contain these tags. Any forward-looking statements in this press release are based on the administration’s current promises and beliefs and are subject to a number of risks, assumptions, and requirements that may be materially identified by real events or outcomes. The statements contained in this press release include, but are not limited to, non-commercial, nanocom commerce, operations, clinical trials, supply chain, strategy, goals and expected deadlines, competition from other companies, and other risks identified in the Nanofom prospects. May 22, 2020) In the case of the first public offering (“Processes”) of Nanofom under “Risk Factors” and in other documents or documents given to the Finnish Financial Supervisory Authority in connection with the Processes. Nanophom warns against placing unreasonable reliance on any future statements made only from the date of its creation. We do not accept the obligation to publicly update or revise any statement that may be expected or that may reflect any change in events, circumstances or circumstances, or that may affect the way in which the actual results differ. Future Statements. Any forward-looking statements contained in this press release represent the views of the Noorform from this date onwards and should not be relied upon as representing any of his views.
About Herentis Pharmacy Plc
Heranitis focuses on treatment modalities to weaken the nervous system, restoring the key mechanism in neurodegenerative disease, prostatitis, to the nervous system. Prostatitis regulates proteins in the body and affects the fate of each protein from digestion to breakdown. Its failure has led to the development of many neurological disorders, including Parkinson’s disease, Alzheimer’s disease, and other disorders, resulting in widespread cycle of protein synthesis, neuralgia, and severe cell stress. CDNF (Biological Protein) belongs to the Herringis Lead Program and Clinical Standards. And xCDNF (a synthetic version of CDNF) is a follow-up to Herantis. CDN (FNF) balances and supports natural proteolysis in the body to protect nerve cells, thereby preventing and counteracting pathogenesis. Heranitis is using this natural ability to treat neurodegenerative diseases. Both CDNF and xCDNF, through their multivariate exercise program, have the potential to improve neurological survival and stop the development of Parkinson’s and other neurological disorders that have a significant therapeutic effect on patients’ quality of life. Herringis shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com
This information is available to you at Cision http://news.cision.com
The following files are available for download
See original content https: //www.prnewswire.com/news-releases/nanoform-technology-delivers-sufulful-results-for-herantis-cdnf-drug-candidate-301372103.html